KALA BIO Announces Chief Executive Officer Transition
Mr. Iwicki stated, “I am proud of the work we have done at KALA utilizing our MSC-S platform, and I am very excited about the potential of our lead product candidate, KPI-012 for the treatment of PCED ...
KALA BIO, Inc.: KALA BIO Announces Chief Executive Officer Transition
KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
Armed robbery in Revesby17h
Enzyme Breakthrough May Revolutionize Biochemistry
Using a series of more than 1,000 X-ray snapshots of the shapeshifting of enzymes in action, researchers at Stanford ...
Armed robbery in Revesby2d
Blood Test Detects Pancreatic Cancer With 85% Accuracy
MANN, the test developed at OHSU could help save lives Jared Fischer, Ph.D., left, and Jose Luis Montoya Mira, Ph.D., cancer ...
ahajournals.org4d
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects
Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk ...
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations ...
eLife4d
Maturation and detoxification of synphilin-1 inclusion bodies regulated by sphingolipids
Due to proteostasis stress induced by aging or disease, misfolded proteins can form toxic intermediate species of aggregates and eventually mature into less toxic inclusion bodies (IBs). Here, using a ...
OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer
OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today ...
Business Wire4d
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...
eLife3d
Tissue-specific responses to TFAM and mtDNA copy number manipulation in prematurely ageing mice
This is an important and solid study that examines the role of TFAM, a protein that helps maintain mtDNA, in mtDNA mutator mice. The authors have demonstrated that TFAM's counteractive role in mtDNA ...
pharmaphorum2d
A history of Abbott and AbbVie
Then, in 1985, Abbott launched the world's first HIV antibody assay. In 1996, one of the first protease inhibitor drugs indicated in combination with other antiretroviral agents for the treatment ...
PipelineReview.com2d
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NEW YORK, NY, USA I 12, 2025 I Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...